Thomas Daniel

Thomas Daniel

Direktor/Vorstandsmitglied bei GOSSAMER BIO, INC.

Vermögen: 8 800 $ am 31.05.2026

72 Jahre
Health Technology
Consumer Services
Commercial Services

Profil

Thomas O.
Daniel
is currently Chairman-Overseers Board at The Scripps Research Institute; Chairman at Locanabio, Inc. since 2017; Chairman at Life Science Cares San Diego LLC; Chairman at Gate Therapeutics; Chairman at Trotana, Inc.; Director at FerruMax Pharmaceuticals, Inc.; Director at Lupus Research Alliance, Inc.; Independent Director at Gossamer Bio, Inc. since 2018; Director at Aspen Neuroscience, Inc. since 2020; Director at Mozart Therapeutics, Inc. since 2020; and Trustee at The Reed Institute since 2017.
Former roles include Chairman-Research Division at Celgene Corp.
in 2016; Independent Director at Zafgen, Inc. from 2016 to 2020; Director at Abide Therapeutics, Inc.; Director at PharmAkea, Inc.; Chief Scientific Officer & Director at Ambrx, Inc.; Director at Alliance for Lupus Research; Director at Pharmaceutical Research & Manufacturers of America; Director at Epizyme, Inc. from 2012 to 2014; Director at Epizyme, Inc.; Director at ImmusanT, Inc. from 2017 to 2019; Independent Director at Juno Therapeutics, Inc. from 2015 to 2018; Executive Director at Catalyst Advisors LP; Independent Director at Magenta Therapeutics, Inc.; Independent Director at Vir Biotechnology, Inc.; Director at Vanderbilt Vascular Biology Center; Director at Sana Biotechnology, Inc.; Independent Director at Larimar Therapeutics, Inc. from 2020 to 2022; Director at Vividion Therapeutics, Inc.; Vice President-Research at Amgen, Inc. from 2002 to 2003; Senior Vice President-Discovery Research at Immunex Corp.
from 2000 to 2002; Venture Partner at ARCH Venture Partners LLC from 2016 to 2021; and Professor at Vanderbilt University.
Education includes an undergraduate degree from Southern Methodist University in 1974; a doctorate from The University of Texas at Austin in 1978; and a doctorate from The University of Texas Southwestern Medical Center in 1978.

Bekannte Unternehmensbeteiligungen

UnternehmenDatumAnzahl der AktienBewertungDatum der Bewertung
04.06.2026 38 095 ( 0,01 % ) 8 800 $ 31.05.2026

Aktive Positionen von Thomas Daniel

UnternehmenPositionBeginn
GOSSAMER BIO, INC. Direktor/Vorstandsmitglied 01.01.2018
Direktor/Vorstandsmitglied -
Direktor/Vorstandsmitglied 01.02.2020
Direktor/Vorstandsmitglied 01.06.2020
Vorsitzender -
Direktor/Vorstandsmitglied 01.03.2017
Vorsitzender -
Corporate Officer/Principal -
Direktor/Vorstandsmitglied -

Ehemalige bekannte Positionen von Thomas Daniel

UnternehmenPositionEnde
░░░░░░░ ░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░ ░░░░░░░ ░░░░░░░░ ░░░ ░░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░░░░ ░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░ ░░░░░░░░░░░░ ░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
Sehen Sie sich die Erfahrung von Thomas Daniel im Detail an

Ausbildung von Thomas Daniel

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Beziehungen

83

Beziehungen ersten Grades

34

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Unternehmensverbindungen

Private Unternehmen34

Health Technology

Health Technology

Health Technology

Finance

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Consumer Services

Consumer Services

Consumer Services

Consumer Services

Health Technology

Commercial Services

Health Technology

Health Technology

Consumer Services

Health Technology

Health Technology

Commercial Services

Health Technology

Commercial Services

Health Technology

Health Technology

Commercial Services

Health Technology

Health Technology

Health Services

Technology Services

Health Technology

Health Technology

Health Technology

Commercial Services

  1. Börse
  2. Insiders
  3. Thomas Daniel